Detalhe da pesquisa
1.
Uncommon MET mutational landscape in a non-small cell lung cancer patient treated with crizotinib: Case report.
Heliyon
; 10(11): e31944, 2024 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38845935
2.
Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.
Cancer Med
; 12(3): 2658-2665, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36000584
3.
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Target Oncol
; 18(4): 585-591, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37310660
4.
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).
Transl Lung Cancer Res
; 12(2): 266-276, 2023 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36895931
5.
Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases.
Front Oncol
; 11: 644282, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33869037
6.
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
Clin Lung Cancer
; 21(5): e497-e510, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32605892
7.
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.
Expert Rev Anticancer Ther
; 18(10): 981-989, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29995451
8.
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).
Clin Lung Cancer
; 23(8): e545-e549, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36210290